Paroxetine for the treatment of interferon-α-induced depression in chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 6, 2002, Pages 1091-1099

  Kraus, M R ^a   Schafer A ^a   Faller, H ^a   Csef, H ^a   Scheurlen, M ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL ACTIVITY; ANXIETY; ARTICLE; CHRONIC HEPATITIS; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEPATITIS C; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOMETRY; QUALITY OF LIFE; RATING SCALE; SUICIDE; ADOLESCENT; AGED; CHEMICALLY INDUCED DISORDER; HOSPITALIZATION; MIDDLE AGED; PATIENT COMPLIANCE; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DEPRESSIVE DISORDER; FEMALE; HEPATITIS C, CHRONIC; HUMAN; INTERFERON-ALPHA; MALE; MIDDLE AGE; PAROXETINE; PATIENT COMPLIANCE; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; SUPPORT, NON-U.S. GOV'T; TREATMENT OUTCOME; HUMANS; MIDDLE AGED;

EID: 0035999141     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01265.x     Document Type: Article

References (42)

1. Epidemiology of hepatitis C
2. Epidemiology of hepatitis C in the West
3. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
4. A population-based serologic study of hepatitis C virus infection in the United States
5. Hepatitis C virus infection
6. Pegylated (40 kDa) interferon alpha-2a in combination with ribavirin: Efficacy and safety results from a phase III randomized, controlled, actively controlled, multicenter study
7. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis
8. Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C
9. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group
10. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
11. Compliance with therapy in patients with chronic hepatitis C. Associations with psychiatric symptoms, interpersonal problems, and mode of acquisition
12. Five cases of interferon-alpha-induced depression treated with antidepressant therapy
13. Sertraline treatment of interferon-alfa-induced depressive disorder
14. Adding low-dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis
15. Successful treatment of interferon alfa-induced mood disorder with nortriptyline
16. Prophylactic treatment of depression induced by interferon-alpha
17. Antidepressant response reversed by interferon
18. Paroxetine for the prevention of depression induced by high-dose interferon alfa
19. Morbidity of chronic hepatitis C as seen in a tertiary care medical center
20. Fluoxetine treatment of depression caused by interferon-alpha
21. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter
22. Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain
23. Cytokines and brain function: Relevance to interferon-alpha-induced mood and cognitive changes
24. Psychiatric side effects of interferon
25. The serotonergic and noradrenergic systems of the hippocampus: Their interactions and the effects of antidepressant treatments
26. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia
27. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders
28. A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: Safety, tolerability and efficacy in continuation phase treatment
29. Reversible hepatotoxicity of paroxetine in a patient with major depression
30. Paroxetine: An overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression
31. A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression
32. Sertraline versus paroxetine in major depression: Clinical outcome after six months of continuous therapy
33. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression
34. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression
35. Serotonergic function in major depression and effect of sertraline and paroxetine treatment
36. Negative immunoregulatory effects of antidepressants: Inhibition of interferon-gamma and stimulation of interleukin-10 secretion